Galvani Bioelectronics
 Galvani Bioelectronics     | |
|---|---|
| Formation | November 2016 |
| Membership | • Amy Altshul • Brad Hirsch • Christopher Corsico • Jordi Parramon • Ken Gabriel • Stephen Gillett • Subesh Williams • Moncef Slaoui • Kris Famm |
| Google/GSK joint venture working on hacking the nervous system | |
Galvani Bioelectronics is a joint venture between GlaxoSmithKline and Alphabet Inc. (Google), which researches implantable devices capable of altering electrical impulses in the body.[1]
Contents
Own words
Galvani is developing therapies to treat disease through implant-based direct modulation of specific neural signals to organs central in chronic disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through use of small and efficient wireless electronics and keyhole surgery.[2]
Problems
Despite the huge amount of money invested, this the technology is not anywhere near a working stage. The company may thus have similarities to Theranos or Moderna.
"The biggest challenge is interpreting the conversation between the body’s organs and its nervous system", the company's president Kris Famm said in 2014. "No one has really tried to speak the electrical language of the body," he says. Another obstacle is building small implants, some of them as tiny as a cubic millimeter, robust enough to run powerful microprocessors. Should scientists succeed and bioelectronics become widely adopted, millions of people could one day be walking around with networked computers hooked up to their nervous systems. As Anand Raghunathan, a professor of electrical and computer engineering at Purdue, puts it, bioelectronics "gives me a remote control to someone’s body."[3]
Known member
1 of the 9 of the members already have pages here:
| Member | Description |
|---|---|
| Moncef Slaoui | Responsible for warp-speed development of experimental Covid-19 jabs up to January 2021. Fired over a "substantiated" sexual harassment claim in March 2021. |
